Similarly, assessment of intra-erythrocytic ROS activity and RBCs premature ageing, evaluated with the DCFDA and anti-CD47 antibody gmeanFI respectively, did not reveal major differences between control and HE-preconditioned RBCs, after HE treatment or during infection (Fig 1F, 1G, 1J and 1K). This evidence concerns the gene CD47 and infection.